PERJETA® IV Infusion Drug use surveillance
Not Applicable
- Conditions
- Breast Cancer
- Registration Number
- JPRN-UMIN000017699
- Lead Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Brief Summary
The incidence of adverse drug reactions (ADRs) in the 261 patients in the safety analysis set was 37.54% (98/261 patients), and there were 223 events. The most common ADRs (in 5% or more of patients) were diarrhoea (12.64%, 33/261 patients), neutrophil count decreased (7.66%, 20/261 patients), and malaise (5.74%, 15/261 patients).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 261
Inclusion Criteria
Not provided
Exclusion Criteria
No criteria
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method